Used as a veterinary sedative and not approved for human use, xylazine has been increasingly linked with opioid overdose deaths in the United States. A growing number of people have been exposed to xylazine in the unregulated opioid supply (especially fentanyl) or in other drugs, particularly in the Northeast. Recent meetings with NIH researchers and clinicians set four domains that merit further evaluation: fentanyl-xylazine overdose, xylazine-associated dermal manifestations, xylazine dependence and withdrawal, and xylazine detection.
In this 50-minute didactic, we will present research updates and priorities within the four domains of xylazine-associated clinical investigation for emergency medicine clinicians. After describing the epidemiology of xylazine exposure, experts will review current evidence regarding, best practices for the management of patients with fentanyl-xylazine overdose, xylazine-associated wounds, and xylazine withdrawal as well as emergency department-based xylazine testing. Experts will answer questions submitted by attendees prior to and during the meeting related to emergency care for patients exposed to xylazine-adulterated opioids. Panelists are national experts in clinical toxicology and addiction medicine, have published critical research findings on xylazine, and are active xylazine researchers. Additionally, the panel has diverse geographic representation from northeast states with high rates of xylazine detection.
Presenters:
Jennifer Love, MD
Lewis S. Nelson, MD
Jeanmarie Perrone, MD
Tony Spadaro, MD
Rachel McFadden, MPH BSN RN CEN
9 июл 2024
